^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG6007

    i
    Associations
    News

    Trials

    Company:
    Roche
    Drug class:
    CD3 agonist, Wilms tumor 1 inhibitor, HLA-A2 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (WP42004) (NCT04580121)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    06/03/2024
    Initiation :
    11/04/2020
    Primary completion :
    08/09/2023
    Completion :
    08/09/2023
    HLA-A
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection